Canadian Investigational & Special Access Drug List (CISADL) 2017 Now Available
By: Chris Doody
The 2017 edition of the Canadian Investigational & Special Access Drug List (CISADL) is now available for purchase.
The Canadian Investigational and Special Access Drug List is a compilation of drugs that are currently not marketed in Canada, and may have Investigational or Special Access status with Health Canada. This list is not endorsed by Health Canada’s Special Access Program. For precise information about the regulatory status of a drug, contact the Special Access Program directly. Entries to the list are contributed to by several Drug Information Centres across Canada and by Canadian drug manufacturers. In cases where non-marketed drugs do not appear on the list, foreign references should be consulted. The content of the list includes generic name and strength/concentration, dosage form, pharmacology/therapeutic use, trade and code name, source (manufacturer/distributor), and comments.
Available in English only/Disponible en anglais seulement.
CSHP Member Price: $75
If you would like to purchase this publication, please submit a completed order form to the Publications Administrator: email@example.com.